When Novo Nordisk engaged in the project of standardising Six Theta® (then Robust Design) in cooperation with Valcon and the Technical University of Denmark, it was with the prospect of gaining new insights into becoming more efficient in their development and achieving a more robust end design.

The Robust Design has since then been mandatory in Novo Nordisk with the result of a shorter ramp-up time in the development phase and an even more sophisticated end product that needs far less QA as the tolerance demands are lowered significantly.

Novo Nordisk has a leading position internationally within the production of medical devices and continues to train new employees in Robust Design.

To support and decide that Robust Design should be mandatory in Novo Nordisk Device R&D required an intense dialogue and training of our highly skilled engineers and production employees. The evident benefits of the Robust Design process carry a huge benefit for our manufacturing economy and improved patient experience in the long term …

Kenneth Strømdahl Senior Vice President of Device R&D, Novo Nordisk